
Neladalkib received accelerated approval for adults with advanced ALK-positive NSCLC after specified prior therapies, supported by durable responses in the ALKOVE-1 trial.
Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses HIV and oncology distinction programs and how these standards bring patients, physicians, and pharmacists together to align care.
Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses HIV and oncology distinction programs and how these standards bring patients, physicians, and pharmacists together to align care.




